HeartBeam Partners with European Consortium to Test At-Home ECG for High-Risk Cardiac Patients
Event summary
- HeartBeam joins the EXIT-CVD research consortium led by UMCG and Philips to advance at-home ECG monitoring for high-risk cardiac patients.
- The HEART-CHECK study will evaluate HeartBeam’s system for early detection of acute coronary syndrome (ACS) in post-discharge patients.
- HeartBeam’s contribution is in-kind, including devices and clinical team expertise, with the study designed as a hybrid effectiveness-implementation trial.
- EXIT-CVD aims to transform cardiovascular disease detection and treatment through 22 clinical studies involving 14,000+ patients across Europe.
- HeartBeam’s system received FDA Breakthrough Device Designation for heart attack assessment at home, though its use remains investigational.
The big picture
HeartBeam’s partnership in the EXIT-CVD consortium aligns with the broader shift toward decentralized, at-home healthcare solutions. The project’s focus on early detection and remote monitoring reflects growing investment in preventive cardiac care, particularly for high-risk patients. With 42 partners across 17 countries and a €27.6 million budget, EXIT-CVD represents a significant collaborative effort to transform cardiovascular disease management in Europe.
What we're watching
- Regulatory Progress
- Whether HeartBeam can secure FDA clearance for heart attack assessment, expanding its system’s use beyond arrhythmia detection.
- Clinical Validation
- The effectiveness of the HEART-CHECK study in demonstrating the HeartBeam System’s ability to reduce hospital readmissions and improve care for high-risk patients.
- Market Expansion
- The pace at which HeartBeam can leverage the EXIT-CVD consortium to enter European markets and compete with established cardiac monitoring solutions.
Related topics
